Partnerships and Licensing

The breadth of our technology and IP protection allows AuraSense Therapeutics to pursue multiple parallel partnerships with pharmaceutical/ biotechnology leaders.   AuraSense Therapeutics is currently engaged in collaborations with several pharma partners to explore the use of SNA™ platform in multiple disease-specific applications.  Areas of additional partnership interest include:

Partnership Type

Field-Specific, Exclusive Collaborations on Therapeutic Targets

Key Elements/ Revenue Sources

  • Disease-specific
  • Multiple pharma manufacturers or third parties as partners
  • Milestones and co-development revenue early in life cycle
  • Royalty arrangements later in life cycle

Impacted AuraSense Technology

  • Gene regulating SNA constructs
  • Immunotherapeutic SNA constructs

Latest News

  • AuraSense Therapeutics Expands Leadership Team

    October 1, 2014go

  • AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer

    July 23, 2014go

  • Bill Gates among new backers of Skokie startup

    June 20, 2014go

  • AuraSense Therapeutics Completes $13.6 Million Series C Equity Investment

    June 17, 2014go

  • New System for Treating Cancer Seen as Hopeful

    June 2, 2014go